Swiss National Bank Tricida, Inc. Transaction History

Swiss National Bank

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$7.31 - $11.85 $429,097 - $695,595	58,700 New	58,700 $568,000
Q2 2021 Aug 06, 2021	SELL	$3.95 - $5.41 $271,760 - $372,208	-68,800 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$4.52 - $7.8 $10,847 - $18,720	2,400 Added 3.61%	68,800 $364,000
Q2 2020 Aug 05, 2020	BUY	$21.21 - $31.55 $591,759 - $880,245	27,900 Added 72.47%	66,400 $1.83 Million
Q1 2020 May 08, 2020	BUY	$18.43 - $38.04 $12,901 - $26,628	700 Added 1.85%	38,500 $847,000
Q4 2019 Feb 06, 2020	BUY	$29.6 - $43.71 $29,600 - $43,710	1,000 Added 2.72%	37,800 $1.43 Million
Q3 2019 Nov 12, 2019	BUY	$29.87 - $42.22 $26,883 - $37,998	900 Added 2.51%	36,800 $1.14 Million
Q2 2019 Aug 02, 2019	BUY	$31.16 - $39.46 $305,368 - $386,708	9,800 Added 37.55%	35,900 $1.42 Million
Q4 2018 Feb 13, 2019	BUY	$23.57 - $32.33 $615,177 - $843,813	26,100 New	26,100 $615,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.